We observed statistically significant acceleration of tumor onset (Fig 2A) in the esco2 heterozygous mutant cohort (T50 = 467 days in esco2hi2865/+; p53zy7/+ cohort vs. 561 days in the p53zy7/+cohort; p<0.0001 based on log-rank test) suggesting loss of esco2 is a tumor driving event. The gene discussed is ESCO2; the disease is neoplasm.